VOLUNTEER IN PFIZER BIONTECH PARTNERSHIP OF COVID-1984 CORONAVIRUS VACCINE TRIALS DEVELOPS GRIEVOUS SORES ON BOTH HER FEET

The injection reaction is called a “fixed drug eruption” and it is present on both feet. Patricia has been unable to walk without a cane since her emergency room visit on November 2nd.

This COVID-1984 vaccine may not be the Mark of the Beast, but I’ll tell you what, I want nothing to do with it regardless of which pharmaceutical company it comes from. We did our best to verify the accuracy of this story before going to press, and have personally contributed to Patricia Chandler’s GoFundMe. However, we advise you to do your due diligence and research it on your own before donating, should you feel so moved to do so. We hope to have either Patricia Chandler or her cousin Rebecca Moore who set up the fundraiser on our Prophecy Podcast program in the very near future, stay tuned for updates
PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY
NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

[link to www.nowtheendbegins.com (secure)]